As part of our series focussing on medicines available in Australia, this review summarises clinically relevant pharmacological properties and key clinical trial data for Abilify Asimtufii in the treatment of adult patients with schizophrenia to help to inform its effective and appropriate use in clinical practice.
Guiding commentary has been provided by Dr Matthew Warden, CMO at Clarity Healthcare.
Please login below to download this issue (PDF)